Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.

In this panel discussion, Dr. Mark Socinski sits down with Dr. Benjamin Levy and Dr. Jyoti Patel to discuss the ways we can use PD-L1 status to identify when monotherapy or combination therapy is appropriate in patients with newly diagnosed metastatic non-small cell lung cancer (mNSCLC).

There’s no denying that biliary tract carcinoma (BTC) presents formidable diagnostic and treatment challenges. That’s why it’s so important for practitioners to stay up to date on the pathophysiology of BTC, as well as current—and even future—first- and second-line treatments. And here to break all those options down for us are Drs. Mitesh Borad and Milind Javle.

This online activity is a concise review of the diagnosis and management of cardiac amyloidosis. Panelists will discuss the biological basis of cardiac amyloidosis, address the challenges of disease presentation, the role of various imaging modalities in the diagnosis, including a detailed discussion of technetium-99m pyrophosphate imaging and provide an overview of current and emerging treatments for transthyretin cardiac amyloidosis.

This online activity is a concise review of the diagnosis and management of cardiac amyloidosis. Panelists will discuss the biological basis of cardiac amyloidosis, address the challenges of disease presentation, the role of various imaging modalities in the diagnosis, including a detailed discussion of technetium-99m pyrophosphate imaging and provide an overview of current and emerging treatments for transthyretin cardiac amyloidosis.

This innovative CPE activity features leading international experts addressing the reduction of residual risk in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD) beyond LDL-C lowering. The program is based on a live satellite symposium and will include the following topics:

• Omega-3 FAs and their use in patients with ASCVD
• Case simulations on personalization of care in ASCVD
• Pharmacist implications of new cholesterol guidelines and CVOT outcomes trials such as REDUCE-IT

For more information, contact Medtelligence at [email protected].

Media: Internet

Despite the progress made in the treatment of neovascular age-related macular degeneration, or nAMD, significant gaps still exist in its diagnosis and treatment. Fortunately, there are ways healthcare professionals can overcome these barriers using proven diagnostic strategies and the latest clinical evidence to raise the potential for more individualized treatment and to optimize outcomes.

In this 15-minute accredited CME audiocast, Dr. Tsao presents 2 cases of patients with advanced NSCLC without a driver mutation and discusses how to manage these patients after first-line treatment. The first case is a patient who progresses on platinum-based chemotherapy, and the second case is a patient who progresses on pembrolizumab-pemetrexed-carboplatin.

A menudo, se puede seleccionar mejor el tratamiento óptimo para pacientes con cáncer colorrectal metastásico después de identificar los oncogenes específicos que controlan el cáncer de cada persona en concreto. Este tipo de enfoque puede facilitar que se escoja con más precisión la quimioterapia y las combinaciones biológicas en la segunda línea y las siguientes, y proporciona orientación sobre si cambiar o continuar con una quimioterapia o una sustancia biológica en concreto.

¿Cómo puede implementar este sistema en su práctica? El dr. Alfredo Falcone está acompañado por los doctores Sebastian Stintzing y Tianshu Liu para compartir sus reflexiones.

In this 15-minute audiocast, Dr. Tsao presents 2 cases of patients with advanced NSCLC without a driver mutation and discusses how to manage these patients after first-line treatment. The first case is a patient who progresses on pembrolizumab therapy, and the second case is a patient who rapidly progresses on pembrolizumab-pemetrexed-carboplatin.